April always brings with it a flurry of personnel changes. China FDA deputy commissioner Yin Li is heading to a leadership position in Sichuan province, Takeda COO Christophe Weber has become CEO and Otsuka has a new chairman, while personnel changes also took place at Aslan and CROs WuXiPRA and George Clinical.

Swiss biopharmaceutical company Telormedix has completed a successful Phase II study of Vesimune (TMX-101) in patients with bladder cancer, and is now hoping to find a partner for the drug by the third quarter of this year.

Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies within the in vitro diagnostics, pharmaceuticals, research/analytical equipment & supplies, and medical device sectors.

Scrip Intelligence has released its latest Roundtable discussion, Capital Efficiency: Managing Biotechs in Straitened Times.